Release
New guidance outlines use of first immunotherapy for children newly diagnosed with type 1 diabetes
The Brief
- Children aged 8 to 17 newly diagnosed with type 1 diabetes now have access to an approved immunotherapy that targets the underlying autoimmune disease.
- Until now, treatment for newly diagnosed children relied solely on managing blood sugar levels with insulin.
- New guidance outlines how the first such immunotherapy should be used.
Why it matters
It is the first approved treatment that targets the autoimmune cause of type 1 diabetes rather than only controlling blood glucose, which may change clinical practice for newly diagnosed children.
Who’s affected
- paediatric endocrinologists and clinicians treating newly diagnosed children
- families of children with newly diagnosed type 1 diabetes
- #type 1 diabetes
- #immunotherapy
- #paediatrics
- #autoimmune disease
- #clinical guidance
For the first time, children ages 8 to 17 who are newly diagnosed with type 1 diabetes have access to an approved treatment that targets the underlying autoimmune disease, rather than solely managing blood sugar levels with insulin.
Timeline
Medical Xpress reports new guidance on the use of the first immunotherapy for children newly diagnosed with type 1 diabetes
Medical Xpress - latest medical and health news stories
New guidance outlines use of first immunotherapy for children newly diagnosed with type 1 diabetes